Anixa Biosciences (NASDAQ:ANIX) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

Anixa Biosciences Stock Up 5.5 %

ANIX stock opened at $3.05 on Wednesday. The firm has a market cap of $97.63 million, a PE ratio of -8.24 and a beta of 0.89. The business has a 50 day moving average of $2.59 and a 200-day moving average of $3.27. Anixa Biosciences has a 12-month low of $2.14 and a 12-month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Tuesday, June 4th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, research analysts expect that Anixa Biosciences will post -0.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Lewis H. Titterton, Jr. bought 10,738 shares of the company’s stock in a transaction on Friday, June 7th. The shares were purchased at an average price of $2.52 per share, for a total transaction of $27,059.76. Following the completion of the transaction, the director now directly owns 848,775 shares in the company, valued at approximately $2,138,913. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Anixa Biosciences news, CEO Amit Kumar acquired 25,000 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were bought at an average price of $2.41 per share, for a total transaction of $60,250.00. Following the completion of the transaction, the chief executive officer now owns 516,925 shares of the company’s stock, valued at approximately $1,245,789.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lewis H. Titterton, Jr. acquired 10,738 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was acquired at an average price of $2.52 per share, for a total transaction of $27,059.76. Following the transaction, the director now directly owns 848,775 shares of the company’s stock, valued at approximately $2,138,913. The disclosure for this purchase can be found here. Insiders have purchased a total of 47,723 shares of company stock worth $119,711 over the last 90 days. Corporate insiders own 22.60% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC raised its position in Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after purchasing an additional 5,183 shares in the last quarter. Staley Capital Advisers Inc. purchased a new stake in Anixa Biosciences during the first quarter valued at about $31,000. Simplicity Wealth LLC purchased a new stake in Anixa Biosciences during the first quarter valued at about $44,000. Finally, International Assets Investment Management LLC raised its position in Anixa Biosciences by 274.6% during the fourth quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock valued at $2,110,000 after purchasing an additional 39,820 shares in the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.